Technology | May 18, 2010

Sensors Track Dose Post-Radiotherapy Treatments

Dose Verification System

May 18, 2010 - Prostate cancer is the most common non-skin cancer in America, affecting one in six men. It is estimated that there are more than 2 million American men currently living with prostate cancer.

Radiation therapy is the second most commonly used treatment for prostate cancer, however, growing concern for the safety of radiological procedures has prompted hospitals to take precautions.

At the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, the state's largest cancer center, radiation oncologists currently implanting a wireless radiation sensor, known as DVS (Dose Verification System). Doctors can now receive data immediately post-treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.
"Traditional radiation therapies rely on knowing the exact location of the tumor, but provide no guidance on quantifying the actual dose being delivered to the tumor," said Glen Gejerman, M.D., co-chief, urologic oncology and director, radiation oncology, John Theurer Cancer Center. "With this implantable device, we can now offer critical same day radiation dose adjustments."

The DVS sensors are 2.1 mm in diameter and 20 mm long, are the first U.S. Food and Drug Administration-cleared wireless implantable sensors designed to assist clinicians in determining the actual dose of radiation being delivered to the tumor.

The sensors are implanted during a minimally invasive procedure and gather data on the precise amount of radiation being delivered to the tumor. Wireless technology transmits the information to a hand-held monitor, and the amount of radiation absorbed is read at the end of each of the daily treatments, enabling doctors to verify that the patient is receiving the prescribed dose.

Deviations in dose delivered to the tumor, or radiation accidentally administered to normal tissue, can have a profound impact on long-term survival rates and quality of life for patients treated with radiation therapy. Accurate delivery of the appropriate dose of radiation is critical to tumor control and cure rate. A long-term clinical study of nearly 230 prostate cancer patients demonstrated statistical significance between dose and benefit, highlighting the importance of measuring the amount of dose delivered. (1)

Reference: (1) Hanks GE, Hanlon AL, Epstein B, et al. Dose Response in Prostate Cancer With 8-12 Years' Follow-Up. Int. J. Radiation Oncology Biol. Phys., Vol. 54, No 2, pp. 427-435, 2002.

For more information: www.siceltech.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Overlay Init